Researchers performed a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA, which included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater. They found that effective doses of MDMA that were administered in a controlled setting, along with adjunctive psychotherapy, were well tolerated and were effective at reducing the symptoms of post-traumatic stress disorder.
Alternative Analysis of the Relative Risk from MDMA Use: "Nutt et al. (2007) attempted to compare the relative dangers of the main types of psychosocial drug, using a series of subjective rating scales. Heroin and cocaine were graded as the two most harmful drugs, whereas Ecstasy/MDMA emerged as one of the least harmful (18th out of 20). Unfortunately, it was unclear how this low harm rating score for Ecstasy/MDMA was given, as they cited no empirical research studies or reviews. Instead, Nutt et al.
"The level of last year ecstasy use by adults aged 16 to 59 in the 2016/17 survey (1.3%, or around 439,000 people) was similar to the previous year (1.5%, or around 492,000 people). There have been small but statistically significant falls compared with a decade ago (1.8% in 2006/07) and the start of measurement by the survey in 1996 (1.7%). Generally, the proportion of 16 to 59 year olds using ecstasy in the last year has been relatively flat throughout the lifetime of the survey, fluctuating between one and two per cent since measurement began in 1996 (Figure 1.4).